Investing in the Future of Cancer Treatment
With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.
On October 30, 2020, ESSA Pharma Inc. delisted from the TSX Venture Exchange. Shareholders wanting more information on how to trade shares on the Nasdaq Exchange should contact their financial advisor or brokerage firm for more information. The delisting of shares does not affect the listing of ESSA shares on the Nasdaq.